{"auto_keywords": [{"score": 0.04617998264114106, "phrase": "next-generation_sequencing_data"}, {"score": 0.00481495049065317, "phrase": "tumor_cellularity"}, {"score": 0.0038953958723049287, "phrase": "novel_bayesian_method"}, {"score": 0.0037336520904376687, "phrase": "purbayes"}, {"score": 0.0034299649219748513, "phrase": "tumor_purity"}, {"score": 0.0032184697893776052, "phrase": "intratumor_heterogeneity"}, {"score": 0.0028944757265206332, "phrase": "paired_tumor-normal_tissue_samples"}, {"score": 0.002658863179011018, "phrase": "finite_mixture_modeling_methods"}, {"score": 0.0023408288327263316, "phrase": "simulated_data"}, {"score": 0.0021049977753042253, "phrase": "varying_conditions"}], "paper_keywords": [""], "paper_abstract": "We have developed a novel Bayesian method, PurBayes, to estimate tumor purity and detect intratumor heterogeneity based on next-generation sequencing data of paired tumor-normal tissue samples, which uses finite mixture modeling methods. We demonstrate our approach using simulated data and discuss its performance under varying conditions.", "paper_title": "PurBayes: estimating tumor cellularity and subclonality in next-generation sequencing data", "paper_id": "WOS:000322337000007"}